Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under Huaxia Fund has a significant holding in Tiger Med. The Huaxia CSI Biotech Theme ETF (516500) increased its holdings by 15,900 shares in the fourth quarter, now holding a total of 75,100 shares, which represents 3.27% of the fund's net value, ranking it as the ninth largest holding [2][5]. - The estimated floating profit from the recent stock price increase is approximately 190,800 CNY for today and 243,300 CNY over the past three days [2][5]. Fund Performance - The Huaxia CSI Biotech Theme ETF (516500) was established on March 4, 2021, with a current size of 130 million CNY. Year-to-date, the fund has experienced a loss of 7.41%, ranking 4868 out of 5563 in its category. Over the past year, it has lost 1.23%, ranking 3929 out of 4429, and since inception, it has lost 42.03% [2][5].